| Syndrome | Interval | Source |
|---|---|---|
| 22q11.2 deletion | Echo and ECG at diagnosis. Any CHD: long-term follow-up, listed as “annual/biennial”. All from 1 y, with or without CHD: periodic arrhythmia, ECG and aortic root screening; no interval stated. | Óskarsdóttir 2023 Table 1 |
| 22q11.2 deletion Adult | Echo at first assessment if none as an adult or in recent years; cardiovascular assessment every 1–2 y. Any CHD: regular follow-up at an adult CHD center. | Boot 2023 Table 1, text |
| Williams | Cardiology, 3-limb BP and echo every 3 mo to 1 y, yearly to 5 y, then every 2 y (Table 3; its text: at least annually through middle childhood). ECG yearly. Sedation and anesthesia: raised risk. | AAP 2020 Table 3, text |
| Down | Newborn echo. Cardiac lesions: cardiology follow-up, even after repair; from 5 y individualized by cardiac history, no interval stated. 12–21 y or older: yearly exam for acquired valve disease. Pulmonary hypertension: raised risk even without a defect. | AAP 2022 |
| Noonan | Echo and ECG at diagnosis; if normal, cardiology every 5 y. On GH: echo about every 6 mo, citing a review. | AHA 2018; Kawai 2026 CQ8 |
| Costello | Urgent cardiology at diagnosis. No known disease: to 2 y, ECG every 3–6 mo and echo every 6 mo; then echo and ECG every 2–3 y to 20 y, every 1–2 y as an adult. Known disease: by type and severity. On GH: every 6 mo for the first year. | Gripp 2019 Table 1, text |
| CFC | Echo and ECG at diagnosis. No cardiac disease: echo every 2–3 y to 20 y, every 3–5 y as an adult. Cardiac disease: the cardiologist sets the frequency. | Pierpont 2014 Table 1, text |
| Turner | TTE at diagnosis, at 9–11 y, after growth or at transition; adults at least every 5–10 y. BP yearly. Dilated aorta or BAV, HTN, CoA: shorter, by Z under 15 y and by ASI, AHI or Z over 15 y; guidelines differ at ASI ≥2.3. | Gravholt 2024 R 4.7, R 4.8, R 4.17, Figures 4–5 |
| Marfan, Loeys-Dietz, vascular EDS | Adult intervals and the pediatric approach on Aortopathy. | See that page |
| Holt-Oram | ECG yearly. | AHA 2018 |
| Jacobsen | Echo at baseline and as needed. | AHA 2018 |
| Tuberous sclerosis | Asymptomatic child: echo every 1–3 y until rhabdomyomas regress. Asymptomatic, all ages: ECG at least every 3–5 y. | Northrup 2021 Table 4, text |
| NF1 | BP at least yearly. Murmur or NF1 microdeletion: cardiology and echo. | AAP 2019 |
| PHACE | Screening echo; yearly echo with a nonobstructive arch anomaly. | Garzon 2016 |
| Cornelia de Lange | Echo in every diagnosed infant and child; no interval. | Kline 2018 |
| Rubinstein-Taybi | Cardiac sonography at diagnosis; no interval. | Lacombe 2024 |
Tap a syndrome name or chip for every row, with age, strength and source.
Consensus, not formally graded (Óskarsdóttir 2023, 22q11.2 Society). Adult rows: not graded, and the authors say to treat all their recommendations as weak, meaning conditional or individualized (Boot 2023).
| Age or group | What and how often | Source |
|---|---|---|
| At diagnosis | Echo and ECG; determine arch sidedness. | Óskarsdóttir 2023 Table 1 |
| To 18 y | Any CHD: long-term follow-up, listed as “annual/biennial” and in every age band; transition to grown-up congenital heart (GUCH) care. | Óskarsdóttir 2023 Table 1 |
| 1–18 y | All, with or without CHD: periodic screening for arrhythmia, ECG abnormalities and dilated aortic root. No interval stated. | Óskarsdóttir 2023 Table 1, footnote d |
| To 18 y | At risk: antiepileptic or neuropsychiatric drugs, hypocalcemia, thyroid disease. Periodic ECG, listed as “annual/biennial”. | Óskarsdóttir 2023 Table 1 |
| Adult | Echo at first assessment if not done as an adult or in recent years; low threshold for aortic root dilation. | Boot 2023 Table 1 |
| Adult | Every 1–2 y: blood pressure, resting heart rate; congenital cardiac (ACHD) and cardiovascular risk assessment. | Boot 2023 Table 1 |
| Adult | Any CHD: regular follow-up at an adult CHD center. No interval stated. | Boot 2023 text |
| Adult | No CHD history: periodic assessment for aortic root dilation, risk factors and hypertension. No interval stated. | Boot 2023 text |
AAP 2020 clinical report; not graded. AAP reports expire at 5 years unless reaffirmed (2025 here); no reaffirmation found.
| Age or group | What and how often | Source |
|---|---|---|
| At diagnosis | Pediatric cardiologist: 3-limb BP (2 arms, 1 leg), echo with Doppler, ECG. | AAP 2020 Table 3 |
| 0–12 mo | Cardiology with 3-limb BP and echo: every 3 mo. | AAP 2020 Table 3 |
| 1–5 y | Cardiology with 3-limb BP and echo: yearly. | AAP 2020 Table 3 |
| 6–18 y | Cardiology with 3-limb BP and echo: every 2 y in Table 3. Its text differs: at least annually through middle childhood, then by the nature and severity of disease. | AAP 2020 Table 3, text |
| Adult | Cardiology with 3-limb BP and echo: every 2 y. | AAP 2020 Table 3 |
| All ages | ECG yearly. | AAP 2020 Table 3 |
| All ages | BP in both arms, murmurs, bruits and pulses each visit. Consider cardiology or nephrology referral for BP >90th percentile for age and height. | AAP 2020 Table 3, text |
| Any age | Table 3: consider CT, MRA or catheterization with severe SVAS, diminished femoral pulses, bruits or suspected long-segment aortic stenosis. Text: decreased pulses, bruits or diffuse thoracic aortic stenosis will require further imaging. | AAP 2020 Table 3, text |
| Any age | Sedation and anesthesia: raised risk of myocardial ischemia, acute hemodynamic deterioration and sudden death, greatest with biventricular outflow tract obstruction. Pediatric anesthesia consultation before procedures (Table 3, to 18 y); plan procedures, particularly nonemergency ones, with pediatric anesthesiologists who know Williams syndrome, in a center with multidisciplinary support for cardiac decompensation. | AAP 2020 Table 3, text |
AAP 2022 clinical report, AHA 2024 statement; not graded.
| Age or group | What and how often | Source |
|---|---|---|
| Birth–1 mo | Echo read by a pediatric cardiologist, whatever the fetal echo showed. Abnormal: refer to pediatric cardiology. | AAP 2022, Birth to 1 Month; AHA 2024 |
| 1 mo–1 y | Infants with cardiac defects: watch for heart failure at every well-child visit as pulmonary vascular resistance falls. | AAP 2022, 1 Month to 1 Year |
| 1–5 y | Cardiac lesions: keep pediatric cardiology follow-up, even after complete repair, for residual lesions and pulmonary hypertension. | AAP 2022, 1 to 5 Years |
| 5–12 y | Individualize cardiology follow-up by cardiac history. No interval stated. | AAP 2022, 5 to 12 Years |
| 12–21 y or older | Examine yearly for acquired mitral and aortic valve disease. Echo for increasing fatigue, shortness of breath, exertional dyspnea, or a new murmur or gallop. Individualize cardiology follow-up by cardiac history; no interval stated. | AAP 2022, 12 to 21 Years or Older |
| Infant, child | Pulmonary hypertension: raised risk even without a structural heart defect (AAP 2022). No national screening recommendation specific to children with trisomy 21 (AHA 2024). | AAP 2022, 1 Month to 1 Year; AHA 2024 |
AHA 2018 rows are written for RASopathies as a group; Kawai 2026 rows are Noonan only (Japanese societies). Costello, CFC: use their own panels.
| Age or group | What and how often | Strength | Source |
|---|---|---|---|
| At diagnosis | Cardiologist with echo and ECG. | Not graded | AHA 2018, Suggested Cardiac Follow-up |
| All ages | No cardiac disease: repeat evaluation every 5 y through childhood and adulthood. | Not graded | AHA 2018, Suggested Cardiac Follow-up |
| All ages | Cardiac disease: follow-up tailored to the findings. | Not graded | AHA 2018, Suggested Cardiac Follow-up |
| Child | Noonan, initial assessment: chest radiograph, 12-lead ECG and TTE. No interval stated. | Strong, level B | Kawai 2026 CQ4 |
| Adult | Noonan: lifelong follow-up; every 3–6 mo to every few years by pathology and severity. | No grade on this sentence | Kawai 2026 text under CQ4 |
| On GH | Noonan, question on HCM: regular TTE follow-up. Evidence text: about every 6 mo, citing a review. | Weak, level C; no grade on the interval | Kawai 2026 CQ8 |
Gripp 2019; not graded.
| Age or group | What and how often | Source |
|---|---|---|
| At diagnosis | Urgent pediatric cardiology: echo, ECG, Holter. | Gripp 2019 Table 1, text |
| 0–2 y | No known disease: cardiologist with ECG every 3–6 mo; echo every 6 mo; Holter for tachycardia or irregular rhythm. | Gripp 2019 Table 1 |
| 2–20 y | No known disease: cardiologist with echo and ECG every 2–3 y; Holter if concern for tachycardia; baseline fasting lipids at 9–11 y; BP at routine visits. | Gripp 2019 Table 1 |
| Adult, >20 y | No known disease: cardiologist with echo and ECG every 1–2 y; lipids every 3–5 y; BP at routine visits. Consider coronary CTA; CTA or MRA if echo suggests aortic dilation. | Gripp 2019 Table 1 |
| All ages | Known disease: by type and severity. Apparently resolved HCM: keep surveillance for recurrence or remodeling. Other apparently resolved disease (arrhythmia, pulmonic stenosis): surveillance as for an adolescent or adult with no known disease. | Gripp 2019 Table 1 |
| On GH | Cardiac evaluation before starting; every 6 mo for the first year, for HCM. | Gripp 2019 text |
Pierpont 2014, expert conference; not graded.
| Age or group | What and how often | Source |
|---|---|---|
| At diagnosis | Echo and ECG (Table 1). Pediatric cardiologist and echo as soon as CFC is recognized or confirmed (text); Table 1 makes the cardiologist conditional on a murmur or suggestive features. | Pierpont 2014 Table 1, text |
| To 20 y | No cardiac disease: echo every 2–3 y; BP each visit. Infancy to 1 y: 24-h Holter if arrhythmias. | Pierpont 2014 Table 1 |
| Adult, >20 y | No previous heart disease: echo every 3–5 y; BP each visit. | Pierpont 2014 Table 1 |
| All ages | All, even after normal echoes or repair: periodic re-evaluation by a cardiologist, who sets the frequency when there is cardiac disease. | Pierpont 2014 Table 1, text |
Gravholt 2024 international guideline; GRADE symbols as printed. Aortic Z scores and ASI: Turner Syndrome Aortic Z-Scores
Guidelines differ. Over 15 y, at ASI ≥2.3 cm/m² without risk factors, Gravholt 2024 (the rows below): every 1–2 y. ACC/AHA 2022: ASI >2.3 at least annually. ESC 2024: every year at ASI 23–25 mm/m² (2.3–2.5 cm/m²). Gravholt 2024, with BAV, HTN or CoA: every 6 mo–1 y at ASI ≥2.3. ACC/AHA 2022, no risk factors: every 5 y in children and 10 y in adults. ESC 2024 applies to women ≥15 y with none of CoA, BAV or uncontrolled HTN. Turner Syndrome Aortic Z-Scores shows ACC/AHA. Figure 4 splits at Z 3.0; the Gravholt bands on that page use 2.5 and 3.5. Gravholt Table 12: use ASI or Z with caution at BSA <1.3 or >2.4 m².
| Age or group | What and how often | Source |
|---|---|---|
| <15 y | No BAV, HTN or CoA: Z <3.0, every 3–5 y. Low risk. | Adapted from Gravholt 2024 Figure 4 |
| <15 y | No BAV, HTN or CoA: Z ≥3.0, every 1–2 y. Moderate risk. | Adapted from Gravholt 2024 Figure 4 |
| <15 y | BAV, HTN or CoA: Z <3.0, every 1–2 y. Moderate risk. | Adapted from Gravholt 2024 Figure 4 |
| <15 y | BAV, HTN or CoA: Z ≥3.0, every 6 mo–1 y. High risk. | Adapted from Gravholt 2024 Figure 4 |
| Adult, >15 y | No BAV, HTN or CoA: ASI ≤2.0, AHI ≤20, Z ≤2.5: every 5–10 y. Low risk. | Adapted from Gravholt 2024 Figure 5 |
| Adult, >15 y | No BAV, HTN or CoA: 2.0 < ASI < 2.3, 20 < AHI < 23, 2.5 < Z < 3.5: every 2–5 y. Moderate risk. | Adapted from Gravholt 2024 Figure 5 |
| Adult, >15 y | No BAV, HTN or CoA: ASI ≥2.3, AHI ≥23, Z ≥3.5: every 1–2 y. Moderate-high risk. | Adapted from Gravholt 2024 Figure 5 |
| Adult, >15 y | BAV, HTN or CoA: ASI <2.3, AHI <23, Z <3.5: every 1–2 y. Moderate-high risk. | Adapted from Gravholt 2024 Figure 5 |
| Adult, >15 y | BAV, HTN or CoA: ASI ≥2.3, AHI ≥23, Z ≥3.5: every 6 mo–1 y. High risk. | Adapted from Gravholt 2024 Figure 5 |
| Adult, >15 y | Consider evaluation for elective repair: ASI >2.5 (AHI >25, Z >4), or ASI >2.3 (AHI >23, Z >3.5) with additional risk factors. Thresholds: Aortopathy. | Adapted from Gravholt 2024 Figure 5 caption |
| Age or group | What and how often | Strength | Source |
|---|---|---|---|
| No CV disease | TTE at 9–11 y, after growth completion or at transition; adults at least every 5–10 y. Figures 2–3 add a cardiology visit at 4–6 y (ECG, BP, imaging only if needed), deferrable to 9–11 y if a cardiologist reviewed neonatal images, ruled out significant lesions and there are no concerning signs or symptoms; CMR or CT at 15–16 y or after growth. | We recommend ⨁⨁○○; figures not graded | Gravholt 2024 R 4.8, Figures 2–3 |
| Fetal | Fetal echo if highly suspected or confirmed prenatally. | We recommend ⨁⨁⨁○ | Gravholt 2024 R 4.1 |
| Newborn | Prenatal diagnosis or suspicion: TTE at day 2–3, sooner if CHD suspected, even if fetal echo was normal. | We recommend ⨁⨁⨁○ | Gravholt 2024 R 4.4 |
| At diagnosis | TTE, all children and adults. | We recommend ⨁⨁⨁○ | Gravholt 2024 R 4.7 |
| At diagnosis | Resting ECG. Later ECGs at intervals set by baseline findings, CHD and course; calculate QTc (Hodges). | We recommend ⨁⨁⨁⨁ | Gravholt 2024 R 4.24; R 4.25 We suggest ⨁⨁○○ |
| Infant, child | Normal heart and aorta, no symptoms: first CMR still recommended; can wait until no general anesthesia is needed. | ⨁⨁○○ | Gravholt 2024 R 4.9 |
| Adolescent, adult | CMR, with or instead of the first echo, in all newly diagnosed; ideally within 12 mo. | ⨁⨁○○ | Gravholt 2024 R 4.10 |
| All ages | Show coronary origins and proximal course in all. | We recommend ⨁⨁○○ | Gravholt 2024 R 4.6 |
| All ages | BP yearly, preferably ambulatory monitoring. | We recommend ⨁⨁○○ | Gravholt 2024 R 4.17 |
| Screening age | Lipid profile no later than the country’s screening age or at transition, then every 3 y. | We recommend ⨁⨁○○ | Gravholt 2024 R 4.22 |
| Pregnancy | Before planned pregnancy or assisted reproduction: imaging, ideally CMR or CT, within 2 y. Low-risk pregnancy: TTE at least once, ideally around 20 weeks. | We recommend ⨁⨁○○ | Gravholt 2024 R 4.32, R 4.36 |
| Pregnancy | With aortic dilation or another risk factor: TTE at least every 12 weeks. | We suggest ⨁○○○ | Gravholt 2024 R 4.37 |
Surveillance by age: Aortopathy, Marfan.
Surveillance, including head-to-pelvis imaging: Aortopathy, Loeys-Dietz.
Aortic and peripheral arterial surveillance: Aortopathy, vascular EDS.
AHA 2018 statement; not graded; no syndrome-specific guideline found.
| Age or group | What and how often | Source |
|---|---|---|
| All ages | ECG yearly, all individuals, for conduction disease with or without CHD. | AHA 2018, Holt-Oram, Cardiac Features |
AHA 2018 statement; not graded.
| Age or group | What and how often | Source |
|---|---|---|
| Baseline | Cardiac evaluation with echo at baseline and as needed. No interval stated. | AHA 2018, General Clinical Recommendations |
Northrup 2021 international consensus; NCCN categories as printed; statements with no mark are Category 3.
| Age or group | What and how often | Strength | Source |
|---|---|---|---|
| Fetal | Rhabdomyomas on prenatal ultrasound: consider fetal echo, to detect high risk of heart failure after delivery. | Category 1, printed at end of paragraph | Northrup 2021 Table 3, text |
| Child, at diagnosis | Echo, especially below 3 y, and 12- to 15-lead ECG. | Category 1, printed at end of paragraph | Northrup 2021 Table 3, text |
| Adult, at diagnosis | Baseline ECG. Echo not necessary without cardiac symptoms or a concerning medical history. | Category 2A | Northrup 2021 Table 3, text |
| Child | Asymptomatic: echo every 1–3 y until rhabdomyoma regression is documented. | Category 1, printed at end of paragraph | Northrup 2021 Table 4, text |
| All ages | Asymptomatic: 12-lead ECG at least every 3–5 y for conduction defects. Symptoms, additional risk factors or significant abnormalities: more often, may include ambulatory event monitoring. | Category 1, printed at end of paragraph | Northrup 2021 Table 4, text |
| Arrhythmia risk | Known arrhythmia or a high-risk ECG: tell the patient some medications and supplements can raise the risk; check with the cardiologist or TSC specialist before starting one. | Category 3 (no mark printed) | Northrup 2021 text |
AAP 2019 clinical report; not graded. AAP reports expire at 5 years unless reaffirmed (2024 here); no reaffirmation found.
| Age or group | What and how often | Source |
|---|---|---|
| Newborn, infant | Cardiac examination, for congenital malformations such as pulmonic stenosis; cardiology referral or echo based on the examination. | AAP 2019 Table 4, Vascular |
| Children | Murmur or NF1 microdeletion: cardiology examination and echo. Whether to screen all with echo is unclear; those with a large deletion should be evaluated. | AAP 2019, Vascular |
| Children | BP at least yearly (Table 4 lists it from 1–5 y; more often as indicated). | AAP 2019 Table 4, Vascular |
| Persistent HTN | Assess large vessels, including renal arteries: Doppler ultrasonography of the aorta and renal arteries, renal arteriography or MRA. | AAP 2019, Vascular |
| Acute, dramatic HR or BP rise | Most experts recommend screening for pheochromocytoma; rare in children. | AAP 2019, Malignancies |
Garzon 2016, consensus-derived; not graded.
| Age or group | What and how often | Source |
|---|---|---|
| At-risk child | Screening echo and MRI with MRA of head, neck and aortic arch at baseline. | Garzon 2016, screening recommendations |
| Abnormal echo | Intracardiac or arch anomaly: urgent pediatric cardiology; cardiac MRI/MRA if arch abnormality suspected. | Garzon 2016, Echocardiogram |
| Children | Nonobstructive arch anomaly: pediatric cardiology with yearly echo. | Garzon 2016, Echocardiogram |
Kline 2018 first international consensus; the level of R10 is in a supplement, not read.
| Age or group | What and how often | Source |
|---|---|---|
| Infant, child | Routine echo in every diagnosed infant and child; in adolescents, guided by symptoms. No interval stated. | Kline 2018, Paediatric medical follow-up |
Lacombe 2024 first international consensus; the grade is in a supplement, not read.
| Age or group | What and how often | Source |
|---|---|---|
| At diagnosis | Cardiovascular evaluation including cardiac sonography. No interval stated. | Lacombe 2024, Cardiovascular system |
What guidelines and society statements recommend, at what age and how often; adult rows labelled